Deciphera expects to submit NDA for Vimseltinib in Q224 and MAA in Q324 in Tenosynovial Giant Cell Tumor TGCT…Results from exploratory ctDNA analysis from INTRIGUE Phase 3 study in 2L GISTpatients with mutations in KIT Exon 11+17/18 published in Nature Medicine; Final overall survival OS results from INTRIGUE study in 2L GIST patients presented at ASCO GI; Cash expected to fund operating and capital expenditures into 2H26…
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DCPH: